Nodular Lymphocyte-Predominant B-cell Lymphoma (formerly NLPHL) · line 2 · Rituximab + CHOP (R-CHOP), 6 cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-R-CHOP |
| ID | IND-NLPBL-2L-RCHOP-TRANSFORMATION |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NLPBL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
Aggressive-track 2L NLPBL for transformation OR multifocal aggressive relapse. Re-uses REG-R-CHOP. Less-intensive alternatives (R-CVP, BR) for indolent-pattern relapse — separate Indication when scope opens. Variant histology (variant-pattern NLPBL) has higher transformation risk — re-biopsy mandatory.
Used By
Algorithms
ALGO-NLPBL-2L- ALGO-NLPBL-2L